Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs HealthSource

By GLP-1 ScorecardUpdated

CoreAge Rx
Site position #1

Higher grade

HealthSource
Site position #105

Lower grade

Score comparison

CoreAge Rx has the higher recorded score — 89.5/100 to 71.2/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

CoreAge Rx scores 89.5/100 (B+).

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueCoreAge Rx +26
92
66
Dose & formulationCoreAge Rx +5
88
83
Clinical oversightCoreAge Rx +13
93
80
Labs & monitoringCoreAge Rx +36
90
54
FulfillmentCoreAge Rx +15
95
80
Contract termsCoreAge Rx +12
67
55
CoreAge Rx · top barHealthSource · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricCoreAge RxHealthSource
WeighScore89.5/10071.2/100
GradeB+C
Site position#1#105
SemaglutideProduct page from $79/mo; navigation $99. Confirm selected quote.$199/mo (all doses, compounded)
TirzepatideFrom $129/mo advertised; confirm selected charge, supply and renewal.$299/mo (all doses, compounded)
CoverageUS only; therapy-specific state restrictions applyAll 50 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedYes
CoreAge Rx

Site position #1 · B+

Strengths

  • Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
  • Advertises the same price across doses and no membership fee
  • Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy

What to consider

  • Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
  • FAQ no-rebill and payment-timing statements differ from the subscription and order policy
  • FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
  • Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
  • Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
HealthSource

Site position #105 · C

Strengths

  • Three GLP-1 options: compounded semaglutide injection, tirzepatide injection, and oral sublingual tirzepatide
  • 24/7 access to care team via HIPAA-compliant platform with unlimited physician messaging
  • Every program covers the cost of medication, supplies, and telehealth visits — no separate pharmacy fee
  • Subscription auto-refund if monthly reassessment is not completed
  • Available in all 50 US states including Alaska and Hawaii with 3–5 day shipping

What to consider

  • No physician names or clinical leadership disclosed on public pages
  • No LegitScript certification found
  • 503A partner pharmacy not named — less transparent than providers disclosing their 503B pharmacy
  • Labs not mentioned on any product page — baseline bloodwork protocol unknown
  • WooCommerce e-commerce storefront may feel more transactional than clinical

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard